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Abstract
Powerful endogenous inhibitory mechanisms are thought to restrict the spread
of epileptic discharges in cortical networks. Similar inhibitory mechanisms
also influence physiological processing. We reasoned, therefore, that useful
information about the quality of inhibitory restraint in individuals with epi-
lepsy may be gleaned from psychophysical assays of these physiological pro-
cesses. We derived a psychophysical measure of cortical inhibition, the motion
surround suppression index (SSI), in 54 patients with epilepsy and 146 con-
trol subjects. Multivariate regression analyses showed that SSI was predicted
strongly by age and seizure type, but not by seizure frequency. Specifically, we
found that patients with exclusively focal epilepsy, and no history of general-
ization, showed significantly stronger cortical inhibition as measured by the
SSI compared to all other groups, including controls. In contrast, patients
with focal seizures evolving into generalized seizures, and patients with gener-
alized genetic epilepsy, showed similar levels of cortical inhibition to controls.
The presumptive focus, when one could be identified, was rarely found in
visual cortex, meaning that the relationship with the epilepsy subtype is likely
to reflect some global difference in inhibition in these subjects. This is the first
reported instance of raised SSI in any patient cohort, and appears to differen-
tiate between patients with respect to the likelihood of their experiencing gen-
eralization of their seizures. These results suggest that such simple
psychophysical assays may provide useful aids to clinical management, partic-
ularly at the time of diagnosis.
Introduction
Most epileptic seizures are thought to arise from impaired
interactions between excitatory and inhibitory elements in
the cerebral and hippocampal cortices. A key role appears
to be played by an endogenous inhibitory restraint mech-
anism arising from the particular arrangement of inhibi-
tory drives onto pyramidal cells, and which serves to
oppose the spread of epileptic activity (Prince and Wilder
1967; Trevelyan et al. 2006; Trevelyan and Schevon 2013).
The inhibitory effects provided by the cortical interneu-
rons (Atallah et al. 2012; Wilson et al. 2012; Pouille et al.
2013) are apparent in recordings of primary visual cortex
neurons during various forms of visual suppression
(Sengpiel et al. 1998). The same inhibitory networks are
also believed to underlie various perceptual phenomena,
collectively known as psychophysical surround suppres-
sion (Tadin et al. 2003, 2006a; Betts et al. 2009; Golomb
et al. 2009; Serrano-Pedraza et al. 2014; Tadin 2015; Yaz-
dani et al. 2015), although this does not discount contri-
butions from other non-GABAergic mechanisms (Tadin
2015). One such test is based on the paradoxical finding
that one’s ability to perceive the direction of movement
of a high-contrast sinusoidal grating is reduced, as the
stimulus size is increased (Tadin et al. 2003). This is
believed to arise from surround suppression in the
motion visual area, MT (Tadin et al. 2003, 2006a; Tadin
2015). This psychophysical phenomenon can be repre-
sented as a single number, the surround suppression
index (SSI), derived from the ratio of the duration
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thresholds of the large and small stimuli. Intriguingly, the
SSI decreases with age (Betts et al. 2005; Yazdani et al.
2015), and is also significantly reduced in subjects with
schizophrenia (Tadin et al. 2006a; Serrano-Pedraza et al.
2014) and depression (Golomb et al. 2009); in each case,
this has been proposed to reflect deficits in cortical
GABAergic inhibition. We therefore investigated whether
changes in SSI are also found in people with epilepsy.
We hypothesized that patients with epilepsy would also
show alterations in visual psychophysical performance,
and that this may be a useful clinical indicator of seizure
risk. We investigated whether the SSI correlated with clin-
ical features such as seizure frequency and seizure type, in
order to determine what, if any, prognostic value might
be provided by this simple psychophysics assay. Specifi-
cally, we had hypothesized that people with epilepsy
might show evidence of reduced cortical inhibition, but
surprisingly, our data suggest otherwise. Contrary to our
original hypothesis, we found that people with generalized
epilepsy showed no difference in SSI from control groups;
and patients with focal epilepsy that did not generalize,
on the other hand, showed a higher SSI. This is the first
identified clinical group to show higher values of this
measure. We suggest that these patients have enhanced
cortical inhibition, which may be a factor in their seizures
being restrained to subregions of the cortex. We discuss
possible clinical implications of these results.
Materials and Methods
Experimental procedures were approved by Newcastle and
North Tyneside Research Ethics Committee (reference
number 09/H0906/90). Participants gave written informed
consent, and were paid a nominal fee for their participa-
tion. Fifty-four patients with epilepsy (mean age,
41.9 years; age range = 17.0–82.3 years; mean duration
16.8 years; duration range = 0–50 years; 30 male) were
recruited via specialist tertiary epilepsy clinics in New-
castle upon Tyne, UK. Seizure types and presumed etiol-
ogy were classified according to the recent ILAE
guidelines (Berg et al. 2010). Seizure frequency was esti-
mated from patient diaries or hospital records. Due to
the well-recognized inaccuracies of patient self-reporting
of seizures (Hoppe et al. 2007), we subdivided seizure fre-
quency into five bins: <1/year, <1/month, <1/week, <1/
day, and >1/day. A total of 146 control subjects (mean
age, 36.6 years; age range = 17.3–69.1 years; 59 male)
were recruited via the Newcastle University volunteer
cohort. Patients filled out a questionnaire regarding con-
current health issues and current medication, and also
completed an Addenbrooke’s Cognitive Examination
(ACE).
All subjects performed a motion discrimination task as
described previously (Tadin et al. 2003; Yazdani et al.
2015). Briefly, drifting sinusoidal grating patches were
presented at two different contrasts, high (peak contrast
92%) and low (2.8%), either on a desktop computer
(Dell) with a CRT monitor, or a tablet computer (Sam-
sung 700T), both running custom written Matlab soft-
ware, implemented using Psychtoolbox3 (Kleiner et al.
2007). The discrimination was a simple two-choice para-
digm, with the gratings moving either left or right. The
stimulus presentation duration was either shortened or
lengthened depending on whether the previous response
was correct or incorrect, resulting in a staircase which set-
tled close to the duration threshold. Three staircases were
run in parallel, with trials interleaved at random. The SSI
was defined as the log ratio of the duration thresholds of
the large and small stimuli.
There was no apparent difference in the SSI measured
on the two different systems (13 subjects [9 patients,
4 controls]; SSIsystem 1 = 0.56 [range 0.16 to 1.56];
SSIsystem 2 = 0.57 [range: 0.26 to 1.23]), so all the data
were pooled. Grating patches were either small (subtend-
ing 0.7° on the retina when the tablet was held at 50 cm
[or 100 cm when using the desktop system], users were
instructed to hold the tablet at about this distance) or
large (5°), and moved either left or right at constant hori-
zontal velocity of 2°/sec. We were able to train most
patients to do these tests very easily, meaning that a data-
set could be attained within 10–15 min. Three patients
were unable to do the test and were excluded from the
analyses. The duration of stimulus presentation was var-
ied according to an adaptive staircase, whereby correct
answers led to shorter presentations of the gratings, while
incorrect answers caused the stimulus duration to be
increased. Three staircase runs were interleaved randomly,
so that the consequences of a correct or incorrect answer
were hidden from the subject during the test. Such stair-
cases rapidly tend toward presentations close to the
threshold duration at which subjects could reliably iden-
tify the direction of movement. The actual value for the
threshold duration, defined as the value where perfor-
mance reached 82% (following Tadin et al. 2003), was
estimated by fitting a psychometric function (Watson and
Pelli 1983) to all trial durations plotted against the binary
answer (right = 1; wrong = 0). A bootstrap resampling
technique was used to derive 95% confidence intervals for
the fitted thresholds, as described previously (Read et al.
2015). The SSI, as defined by Tadin et al. (2003), is the
log ratio of the threshold durations (TD) for the large
and small, high-contrast stimuli, calculated as follows:
SSI ¼ log10ðTDhigh:large=ðTDhigh:smallÞ
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Table 1. Patient data.
Index Gender
Age
(years)
Age at
onset (years)
Duration of
epilepsy (years) Presumed location
Seizure
frequency Antiepileptic drugs SSI
Focal+
EP1 M 49 Not known Not known Temporal 3 VPA/PHT/CLB/PGB 0.09
EP5 M 35 34 1 Frontal 2 CBZ 0.28
EP6 F 26 1 25 Temporal 2 VAL/LTG/PGB/CLB 0.34
EP13 M 61 27 34 Unknown 3 LTG 0.10
EP14 F 27 26 1 Temporal 1 None 0.40
EP18 F 55 41 14 Temporal 2 None 0.19
EP19 M 33 3 30 Possible frontal 4 VPA/CLB/PER/PHT 0.08
EP24 F 22 7 15 Occipital (L) 3 TPM/ZNS 0.19
EP27 M 68 58 10 Unknown 1 LTG 0.05
EP30 F 58 11 47 Unknown 3 LEV/PER 0.21
EP31 F 57 28 29 Temporal 4 LTG/PGB 0.24
EP33 M 82 51 31 Temporal 3 LTG 0.07
EP36 M 59 47 12 Parietal 2 PHT/LTG/LEV/MDZ 0.10
EP49 F 33 4 29 Temporal (L) 4 OXC 0.30
EP51 M 30 17 13 Unknown 2 LTG/TPM 0.75
EP53 M 33 18 15 Frontal 3 VPA/LEV 0.65
EP56 M 68 64 4 Temporal 2 LEV 0.12
EP57 M 44 9 35 Right hemisphere 3 ZNS/LEV/VPA 0.79
Focal
EP3 M 68 12 56 Temporal 1 CBZ/LEV/LTG 0.21
EP4 M 70 64 6 Temporal 4 LTG 0.11
EP7 F 67 6 61 Temporal 3 PHT/LTG/LEV 0.11
EP17 M 42 7 35 Temporal 3 CBZ/LEV 0.42
EP20 F 28 11 17 Frontal (L) 5 RTG/CLB/CBZ/LEV 0.87
EP2I M 52 21 31 Frontotemporal (L) 3 CBZ/LEV 0.72
EP23 F 62 13 49 Temporal 4 CBZ/ZNS 0.71
EP25 F 43 7 36 Temporal 2 ZNS 1.01
EP26 F 73 54 19 Unknown 1 VPA 0.19
EP32 M 56 40 16 Temporal 4 LEV/RIG 0.66
EP34 F 34 21 13 Temporal 4 PER/LEV/PGB 1.24
EP35 M 22 16 6 Temporal 3 CBZ/TPM/CLB 1.34
EP37 F 27 23 4 Temporal 4 PER 1.00
EP38 F 25 0 25 Multifocal 4 LEV/LTG/CLB 0.88
EP39 M 34 31 3 Temporal 5 TPM/LTG/OXC 0.69
EP41 M 26 16 10 Temporal 5 CLB/LCM/LEV/ZNS 0.52
EP42 F 31 6 25 Temporal 3 LTG / PGB 1.02
EP44 M 42 14 28 Frontotemporal 4 VPA/LTG 0.50
EP45 M 35 11 24 Frontal 4 VPA/PGB/ESL/PB 0.48
EP46 F 31 5 26 Temporal lobe 4 PGB/LEV/CBZ/PHT/CLB 0.65
EP47 M 50 45 5 Anterior temporal (L) 4 ZNS 0.87
EP48 F 62 46 16 Temporal 4 CBZ/CLB/VPA 0.03
EP50 F 26 22 4 Temporal 2 None 0.79
EP55 M 51 36 15 Temporal 3 LEV 0.57
GGE
EP8 F 41 5 36 Generalized 5 None 0.48
EP9 M 18 12 6 Generalized 1 VPA 0.43
EP10 M 17 16 1 Generalized 2 VPA 0.31
EP11 M 55 54 1 Unknown 2 VPA 0.42
EP12 M 18 17 Only 1 seizure Occipital 1 None 0.22
EP15 M 22 22 0 Generalized 2 None 0.36
EP16 M 18 17 1 Generalized 1 None 0.29
EP22 F 29 20 9 Generalized 3 LEV 0.82
EP28 M 51 5 46 Possible frontal 3 VPA/LEV/CBZ 0.27
EP29 F 23 11 12 Generalized 4 ZNS 1.19
EP40 F 22 22 0 Generalized 5 LEV 0.28
EP43 F 55 15 40 Generalized 2 PRM/PGB 0.26
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Although the results for low-contrast stimuli are not
incorporated directly into this index, they provide an
important control assay of whether the participants were
doing the psychophysics test correctly and prove that the
high-contrast stimulus was well above their contrast
threshold. Since the threshold duration for a large high-
contrast stimulus is typically longer than for a small stim-
ulus (Tadin et al. 2003; Yazdani et al. 2015), the SSI
tends to be positive, and increasingly positive values indi-
cate stronger surround suppression.
All statistical analyses were performed using the Matlab
statistical toolbox. Comparisons of two regressions were
performed using ANCOVA (analysis of covariance, aoctool
in Matlab). Multivariate linear regression used the fitlm
tool in Matlab, treating the epilepsy subtypes as “categori-
cal.” Model comparisons were made using the adjusted
R2 values, which takes into account the effect of adding
predictors on R2. Results were considered significant if
P < 0.05.
Results
We present an analysis of the performance on a simple
visual psychophysics test of 54 patients with a confirmed
diagnosis of epilepsy, and 146 control subjects. Details of
the individual patients are provided in Table 1. Results
from a subset of the control group (36 of the 146) were
published as part of a prior study (Yazdani et al. 2015);
the extended dataset we show here confirm our previous
reports that the SSI shows a highly significant negative
correlation with age (P < 0.001; Fig. 1E [green dia-
monds]). The epilepsy cohort showed a similar, highly
significant regression with age (P < 0.001), and further-
more, regression analysis showed that the epilepsy group
Frequency grading
<1/year 1
<1/month 2
<1/week 3
<1/day 4
>1/day 5
Refer Table 3 for the code of the drug lists. SSI, surround suppression index.
Figure 1. Altered psychophysical measure of surround inhibition in patients with epilepsy. (A–D) Threshold durations for discriminating the
direction of movement, for large (5° field of view) and small (0.7°) gratings, at high (92%) and low contrast (2.8%), in the control and epilepsy
cohorts, plotted against age of subject. The error bars for the individual data points indicate the 95% confidence interval for each, as described
in our previous paper (Yazdani et al. 2015). (E) The motion surround suppression index for the control and epilepsy cohorts plotted against age
of subject.
Table 1. Continued.
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was highly significantly different from the control group
(F1,196 = 7.15, P < 0.0001), both with respect to the inter-
cept (P < 0.0001) and the gradient (P < 0.0001) of the
relationship with age. Analysis of the component tests
(Fig. 1A–D) indicated that the epilepsy cohort differed
only on the tests involving large high-contrast stimuli
(F1,196 = 10.08, P = 0.0012), which importantly is the one
in which surround inhibition is likely to be manifest
(Barlow and Mollon 1982; Sengpiel et al. 1998) (other
tests: small high contrast, F1,196 = 1.33, P = 0.250; small
low contrast, F1,102 = 0.02, P = 0.875; large low contrast,
F1,104 = 3.51, P = 0.064; all nonsignificant). These results
suggest that grouped together, the epilepsy patients have
a higher SSI, suggestive of enhanced cortical inhibitory
mechanism, when compared with age-matched control
subjects.
We next subgrouped the epilepsy cohort with respect
to seizure type (Berg et al. 2010) and seizure frequency.
The cohort was subclassified into three groups: those
patients with focal epilepsy with a history of generalized
seizures (F+, n = 19), focal epilepsy without generalizing
seizures (F, n = 24), and generalized genetic epilepsy
(GGE, n = 11) (Fig. 2). There was no difference in per-
formance on the Addenbrooke’s Cognitive Examination
between the groups (F+, ACE = 90.5  6.2 [mean  SD],
range: 72–96; F, ACE = 88.5  6.3, range: 73–99; GGE,
ACE = 92.0  4.1, range: 85–100). Seizure frequency was
binned into five groups (Fig. 3). Initial inspection of these
plots suggested that, in addition to the effect of age, both
seizure type and frequency might also influence the SSI.
We therefore examined the relative importance of these
three potential predictors (age, seizure subtype, and sei-
zure frequency) of SSI by performing multivariate regres-
sion analyses on progressively more complex models
(Table 2).
We first considered the subclassification into seizure
types, independent of the age and seizure frequency. The
distribution of SSI values differed significantly between
the four groups (F+, F, GGE, and controls; ANOVA,
F3,196 = 11.66, P < 0.0001; Fig. 2A); t-test analyses indi-
cated that the F group was the outlier. The previously
noted regression with age was apparent for each subgroup
individually (Fig. 2B), although this was only significant
for the two larger sample groups, F+ (n = 19, R2 = 0.259,
P < 0.05) and F (n = 24, R2 = 0.527, P < 0.001), but
not for GGE (n = 11, R2 = 0.144, n.s.). Next, when con-
sidering both age and epilepsy diagnosis together, we
found marked increases in the adjusted R2 values when
first subdividing the complete dataset (age alone,
R2 = 0105, Table 2) into controls and epilepsy subjects
(adjusted R2 = 0.183), and then further subclassifying into
the F+, F, and GGE subtypes (adjusted R2 = 0.318).
Importantly though, the age and subtype model was not
further improved by adding the seizure frequency (ad-
justed R2 = 0.315). This lack of effect of seizure frequency
was better appreciated when this predictor was plotted
for the three seizure subtypes individually (Fig. 3B–D).
These plots also show that in our samples, the F patients
tended toward a higher seizure frequency (the median fre-
quency bin for GGE was “<1 month,” for F+ it was “<1/
Figure 2. Surround suppression is altered in patients with focal nongeneralizing seizures, but is not affected by seizure frequency. (A) Box plot
of SSIs for the subjects grouped by seizure type. The box limits represent the first/third quartiles, with the median indicated by the middle line
and the whiskers extending to data points that are <1.5 interquartile range beyond the box. The data for the group with focal seizures without
generalization (red) were highly significantly different from all other groups (**P < 0.01). (B) Regression of SSI with respect to age for the same
groups of subjects. SSI, surround suppression index.
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Figure 3. Surround suppression is not affected by seizure frequency. (A) Box plots of the SSIs with respect to frequency of seizures for the
pooled epilepsy cohorts, and for each of the three subgroups of epilepsy patients, plotted separately (B–D, all nonsignificant). SSI, surround
suppression index.
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week,” and for F it was “<1/day”). This mismatch in the
seizure frequency between the groups can explain the
increase in R2 going from a model using just “Age” to
one using “Age + Frequency” (Table 2): in this case, in
which seizure subtype was ignored, the subtype acts as a
hidden predictor and distorts our interpretation of the
effect of frequency. The important comparison is that a
model using all three predictors actually explains no more
of the variance than one using just age and seizure sub-
type. The regression table for the three-predictor model
indicates highly significant P values for the control inter-
cept and slope (P << 0.001), and for the change in inter-
cept and slope for the F group (P << 0.001), but for no
other comparison, and notably frequency was nonsignifi-
cant (P = 0.632). We conclude, therefore, that only age
and seizure subtypes were significant predictors of SSI.
One possible confounding issue was that certain
antiepileptic drugs (AEDs) are known to interact with the
GABAergic system, and indeed this is presumed to con-
tribute to their clinical effect (Walker and Surges 2009).
We therefore analyzed the pattern of medication of the 54
patients who participated in the study. Collectively,
patients were on 17 different medications (Table 3, Fig. 4).
Seven patients were recruited at the time of diagnosis and
were not therefore on medication when they did the psy-
chophysical tests; 18 patients were on monotherapy, and
the rest were on multiple drugs (Fig. 4A). The GGE patient
group tended to be on a lower numbers of drugs (1.00
drugs/subject), with the F+ and F groups taking similar
numbers (1.84 and 2.33, respectively). The most commonly
prescribed drugs were levetiracetam (19 patients),
lamotrigine (14 patients), and sodium valproate (13
patients), but notably the pattern of drug prescriptions for
the patients with generalized seizures (GGE and F+) and
those without (F) were broadly similar (Fig. 4B). Since
the psychophysics test is presumed to reflect cortical
GABAergic function, we subdivided the epilepsy cohort
into two groups according to whether or not they were on
drugs that are known to interact with GABA (Table 3; note
that both groups contain people on polypharmacy). Nota-
bly, there was no difference in the SSI for these two groups
(non-GABA drug group, n = 27, SSI = 0.40  0.37; GABA
group, n = 27, SSI = 0.49  0.36). Furthermore, including
the presence or absence of drugs with GABAergic effects as
a predictor in the regression analyses did not explain any
additional variance (adjusted R2 = 0.316). This was also
true when the regression analyses were restricted to the epi-
lepsy subjects (age/epilepsy subtype, adjusted R2 = 0.475;
age/epilepsy subtype/GABA effect, adjusted R2 = 0.464).
Finally, we examined whether patients with low versus high
SSI scores (subdivided at the median SSI) were predomi-
nantly within the GABAergic/non-GABAergic drug interac-
tions groups (Fig. 4C). There was no significant difference
between the low and high SSI patients (Fisher’s exact tests),
either for all the patients pooled irrespective of seizure type
or for the generalized and focal groups alone. We con-
cluded, therefore, that drug interactions do not underlie
the effects of seizure type and age on the SSI.
Discussion
SSI may provide biomarkers of epilepsy
The results of most general interest are the relationship
between SSI with respect to the likelihood of seizure gen-
eralization, and the lack of a relationship with seizure fre-
quency, especially since these are counter to what might
have been anticipated. Our original hypothesis had been
that people with epilepsy would have a reduced SSI,
indicative of lowered inhibitory restraint. Instead, we
found that as a group, patients with generalized seizures
are no different from control subjects, but those with focal
epilepsy that does not generalize (F), have a raised SSI.
This surprising finding contrasts with the reduced SSI in
other groups: people with schizophrenia (Tadin et al.
2006a), depression (Golomb et al. 2009), low IQ (Melnick
et al. 2013), and aged subjects (Betts et al. 2005; Yazdani
et al. 2015). Notably, most of the previously noted associ-
ations with increased SSI are “good” factors (youth [Betts
et al. 2005; Yazdani et al. 2015] and high IQ [Melnick
et al. 2013]). The significantly raised SSI in the F patient
group, relative to the other epilepsy groups, could not be
explained by differences in age or IQ (there was no differ-
ence in ACE scores between the epilepsy groups). And
Table 2. Model comparisons.
Models R5 Adjusted R2
SSI versus Age 0.105 –
Age, epilepsy 0.195 0.183
Subtype, freq 0.170 0.144
Age, freq 0.200 0.192
Age, subtype 0.342 0.318*
Age, subtype, freq 0.342 0.315
Model parameters (age, subtype)
Gradient (year1) Intercept
Controls 0.0041  0.0011** 0.484  0.047**
F+ 0.0071  0.0031 0.566  0.147
F 0.0164  0.0031** 1.362  0.141**
GGE 0.0088  0.0047 0.694  0.167
Note that for the control group statistics, what is being tested is
significant difference from zero, and for the other groups, it is the
significant difference from the controls.
The optimal model is indicated by *, and the parameters for that
model are indicated by **P << 0.001.
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while we cannot fully discount a confounding effect of
concurrent depression, this condition is not known to be
differentially associated with the presence, or absence, of
generalized seizures in patients with focal epilepsy.
There are parallels between our study and a previous
study of patients with migraine, who also showed evi-
dence of increased suppression in a closely related percep-
tual task measuring contrast perception (Battista et al.
2011). The intriguing possibility is that in these patients
with focal (nongeneralizing) epilepsy, the pathological
activity is kept focused by an enhanced inhibitory
restraint. Furthermore, it may therefore be possible to
assess the quality of this restraint in regions of the cortex
far removed from the focal pathology, as we do here with
an assay of visual cortical function that appears to have
relevance to foci elsewhere in the cortex. This presents an
interesting question concerning whether the enhanced
surround inhibition is independent of the epilepsy, or has
arisen in reaction to the pathology, which will be
addressed in future studies requiring longitudinal,
repeated testing of patients from the time of diagnosis.
A large body of evidence has linked suppression of
motion perception to processing in the motion area of
visual cortex (cortical area MT) (Tadin et al. 2006b,
2003), equivalent approximately to the border between
Brodmann areas 19 and 37 (see Tadin 2015 for an exten-
sive review of this literature, including discussion of the
involvement also of other parts of the visual system).
With one exception (Ep12), this cortical area was not
considered to be the focus of pathology for any of our
patients (Table 1), which begs the question then of why
measuring inhibitory function in a specific location may
Figure 4. Patterns of medication for the three subgroups in the patient cohort. (A) Cumulative frequency plots of the proportions of the
patients in the three groups taking different numbers of antiepileptic drugs (AEDs). (B) Histogram showing the numbers of patients in each
group taking the different AEDs. The abbreviations of the drugs are given in Table 3. (C) Proportions of patients with either low SSIs or high
SSIs who are on medication that either interacts with, or is considered independent of, the GABAergic system. In each case, the cohort was
subdivided at the median score SSI (Ci, all patients, n = 27 for both low and high SSI groups; Cii, patients with generalized epilepsy [F+ and
generalized genetic epilepsy], n = 15 for both groups; Ciii, patients with exclusively focal epilepsy [F], n = 12 for both groups). SSI, surround
suppression index.
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be relevant to epilepsy with a focus in a different part of
the brain. There are parallels here with previous studies
showing how SSI correlates with the occurrence of other
brain pathologies not necessarily linked to visual process-
ing, including schizophrenia (Tadin et al. 2006a) and
depression (Golomb et al. 2009). Another study also
showed an increase in contrast suppression in patients
with migraine (Battista et al. 2011). We speculate that the
answer lies in how inhibition may be affected globally, for
instance, arising during development, or reflecting certain
brain states, or under the influence of neuromodulators.
If this is so, then an assay of inhibitory function at a par-
ticular location may also reflect inhibition in other areas
that are relevant to the pathological condition.
The seizure frequency data are also interesting, although
it needs to be interpreted with some caution, because this
can be very difficult to estimate accurately (Hoppe et al.
2007). For instance, ambulatory recordings have shown
that there is under-reporting of many seizure events (Cook
et al. 2013). With this caveat in mind, it is interesting to
contrast the absence of any relationship between seizure
frequency and SSI with that regarding the likelihood of sei-
zure generalization: this difference suggests that seizure ini-
tiation and seizure generalization may occur through
different mechanisms modulated by different factors.
For all groups, the association of SSI with age persisted,
consistent with previous studies (Betts et al. 2005; Yaz-
dani et al. 2015). It is noteworthy that the largest
increases of SSI were found in young patients without a
history of seizure generalization, and that this group
showed a significantly steeper association. This may repre-
sent a progressive change in the risk of seizure generaliza-
tion; undoubtedly some people in this group will at some
stage in their life experience a generalized seizure, mean-
ing that they would have moved epilepsy groups in our
analysis. At an early age, then, these people might be con-
sidered “latent” with respect to seizure generalization.
Furthermore, given the association between seizure gener-
alization and sudden unexpected death in epilepsy
(SUDEP), we speculate that having a relatively low SSI at
the time of diagnosis, even without a history of seizure
generalization, may be a poor prognostic indicator. Again,
we will benefit from longitudinal studies of progression
and variability in SSI in individuals with epilepsy.
Drug interactions were difficult to assess because the
diverse drug regimes in our patient cohorts made it difficult
to control for this variable. Since the SSI is considered to
reflect cortical GABAergic interactions, we focused our
attention on drugs that are known to modulate GABAergic
activity. We performed several different analyses, showing
that the different epilepsy cohorts had broadly similar
pharma profiles, nor was there any apparent difference
between patients with high and those with low SSIs. It
remains a possibility that some drugs may interfere with
performance on the test, but this is highly unlikely to
explain the differences between the epilepsy groups.
Usefulness for clinical practice
We have shown how a simple visual psychophysics test
may provide a convenient and entirely noninvasive means
of assessing the function of cortical networks in the clini-
cal setting. These tests required only minimal training,
and can provide a measure of SSI within 10 min. We
adapted these to run on a tablet computer, thus providing
a portable means of testing, which the patients could use
either in the clinic, or in their own home. Importantly,
the data collected on these tablet computers in the com-
munity and at clinics matched previous studies performed
in laboratory conditions, in showing a progressive and
highly significant decline in the SSI with increasing age.
The main clinical implication of our study relates to the
association of SUDEP with generalized seizures. SUDEP
affects approximately 1 in 1000 patients with epilepsy per
year, and the single biggest risk factor is the presence of
uncontrolled generalized tonic-clonic seizures, increasing
the risk to 1 in 150 patients per year (Nashef et al. 2007;
Duncan and Brodie 2011; Shorvon and Tomson 2011).
Currently, there are no reliable biomarkers of SUDEP risk.
Any biomarker that reliably predicted patients at risk of
generalized seizures would therefore be hugely beneficial
for risk stratification, counseling, and treatment strategy.
To be useful, such a biomarker would ideally be present
Table 3. Subdivision of the drugs into those that are known to
affect the GABAergic system, and those that are thought to have
their effect independent of GABA.
No documented GABA effect
CBZ Carbamazepine
ESL Eslicarbazepine
LCM Lacusamide
LEV Leveliracetam
LTG Lamolrigine
OXC Oxcarbazepme
PER Perampanel
PGB Pregabalin
PHT Phenyloin
Known GABAergic interactions
CLB Clobazam
MDZ Midazolam
PB Phenobarbital
PRM Primidone
RTG Retigabine
TPM Topiramatc
VPA Valproic acid
ZNS Zonisamide
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before the occurrence of a first generalized seizure. We sug-
gest that the SSI may prove to be a promising candidate
for such a biomarker: the raised SSI seen in patients who
have never previously had a generalized seizure indicating
a lower risk of SUDEP, whereas the normal SSI seen in
patients with a history of generalized seizures indicating a
higher risk. Since SSI also tends to decrease with age, this
index will be most useful for patients who develop, or are
diagnosed with epilepsy early in life.
Our groupings according to seizure types were based
on seizures that had already occurred, and we studied
patients at only a single time point. We therefore cannot
know whether the patients with generalized seizures had a
normal SSI initially, and nor can we know whether
patients with an increased SSI will remain free of general-
ized seizures in the long term. It is noteworthy, however,
that the decline of SSI with age is significantly more steep
in the F group than for other groups, which may mean
that their risk of generalizing seizures, and therefore by
extension, of SUDEP, may also change. These questions
can only be addressed by further longitudinal studies.
Nevertheless, given that visual psychophysical measures
are simple, quick, and safe to administer, we feel that
these further studies are justified.
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